Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.12 USD | -1.75% | -0.90% | -23.63% |
04:51pm | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.63% | 6.84B | |
+2.76% | 108B | |
+10.19% | 105B | |
+1.57% | 23.46B | |
-12.32% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.12% | 17.19B | |
+6.15% | 13.99B | |
+36.35% | 12.53B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- BofA Securities Initiates Coverage on Cytokinetics With Neutral Rating, $49 Price Target